Literature DB >> 18577182

Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007.

H K Graham1, M Horn, A W Trafford.   

Abstract

The myocardial extracellular matrix (ECM), which preserves the geometry and integrity of the myocardium, is a dynamic structure whose component proteins are maintained by a finely controlled homeostatic balance between deposition and degradation. One of the key targets in cardiology is the elucidation of the molecular mechanisms which mediate pathological remodelling of this matrix causing the transition from compensatory hypertrophy to congestive decompensated heart failure. In response to injury or increased workload, cardiac remodelling including myocyte hypertrophy, develops as the heart attempts to compensate for increased wall stresses. Persistence of these stresses over extended time periods leads to disruption of ECM homeostasis resulting in irreversible maladaptive cardiac remodelling, ventricular dilatation and finally heart failure. ECM remodelling is regulated by the matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs). Clinical studies and experimental models of cardiac disease states have reported alterations in the balance between the MMPs and TIMPs in the failing heart and crucially at intermediate time points in the progression to failure. This article reviews the recent clinical, genetic and experimental approaches employed to compare ECM, MMP and TIMP profiles in healthy, compensated and failing hearts and identifies common themes in the perturbation of ECM homeostasis in the transition to heart failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577182     DOI: 10.1111/j.1748-1716.2008.01881.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  35 in total

1.  Thick acellular heart extracellular matrix with inherent vasculature: a potential platform for myocardial tissue regeneration.

Authors:  Udi Sarig; Gigi C T Au-Yeung; Yao Wang; Tomer Bronshtein; Nitsan Dahan; Freddy Y C Boey; Subbu S Venkatraman; Marcelle Machluf
Journal:  Tissue Eng Part A       Date:  2012-07-19       Impact factor: 3.845

Review 2.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 3.  Cardiovascular effects of leptin.

Authors:  Gary Sweeney
Journal:  Nat Rev Cardiol       Date:  2009-12-01       Impact factor: 32.419

Review 4.  Cardiac myocyte-fibroblast interactions and the coronary vasculature.

Authors:  Stephanie L K Bowers; Troy A Baudino
Journal:  J Cardiovasc Transl Res       Date:  2012-09-18       Impact factor: 4.132

Review 5.  Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.

Authors:  Hassan K Awada; Mintai P Hwang; Yadong Wang
Journal:  Biomaterials       Date:  2015-12-29       Impact factor: 12.479

Review 6.  Pregnancy as a cardiac stress model.

Authors:  Eunhee Chung; Leslie A Leinwand
Journal:  Cardiovasc Res       Date:  2014-01-20       Impact factor: 10.787

7.  Activation of GPR30 inhibits cardiac fibroblast proliferation.

Authors:  Hao Wang; Zhuo Zhao; Marina Lin; Leanne Groban
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

8.  MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA.

Authors:  Paras Kumar Mishra; Naira Metreveli; Suresh C Tyagi
Journal:  Cell Biochem Biophys       Date:  2010-07       Impact factor: 2.194

9.  The acellular myocardial flap: a novel extracellular matrix scaffold enriched with patent microvascular networks and biocompatible cell niches.

Authors:  Jason B Schulte; Agneta Simionescu; Dan T Simionescu
Journal:  Tissue Eng Part C Methods       Date:  2013-01-16       Impact factor: 3.056

10.  Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.

Authors:  Dawn A Delfín; Kara E Zang; Kevin E Schill; Nikita T Patel; Paul M L Janssen; Subha V Raman; Jill A Rafael-Fortney
Journal:  Neuromuscul Disord       Date:  2012-06-29       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.